Olumiant® Olumiant Olumiant [Member] Olumiant [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Derivative liability, notional amount Derivative Liability, Notional Amount Damages awarded, value Loss Contingency, Damages Awarded, Value Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Olanzapine Portfolio Olanzapine Portfolio [Member] Olanzapine Portfolio Underlying Security Market Price Change Underlying Security Market Price Change, Percent Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Proceeds from sale of product rights Proceeds from Sale of Intangible Assets All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Acquired in-process research and development (Note 3) Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Writeoff Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Offsetting Assets [Table] Offsetting Assets [Table] Payments to acquire businesses Payments to Acquire Businesses, Gross Schedule of the amounts recognized for assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Other diabetes Other Diabetes [Member] Other Diabetes [Member] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Accounts receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Other–net, (income) expense (Note 11) Other–net, (income) expense Nonoperating Income (Expense) Number of pending lawsuits Loss Contingency, Pending Claims, Number Commitments and Contingencies (Note 9) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Other receivables Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of research and development assets acquired other than through business combination Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Geographical [Axis] Geographical [Axis] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] 4.95% Notes Due 2063 4.95% Notes Due 2063 [Member] 4.95% Notes Due 2063 Current Liabilities Liabilities, Current [Abstract] Purchases of in-process research and development Payments to Acquire in Process Research and Development Business Acquisition [Line Items] Business Acquisition [Line Items] Employee benefit trust Common Stock, Shares Held in Employee Trust Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net of allowances of $13.4 (2023) and $16.0 (2022) Accounts Receivable, after Allowance for Credit Loss, Current Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Line of Credit Line of Credit [Member] Schedule of net pension and retiree health (benefit) cost Schedule of Net Benefit Costs [Table Text Block] Litigation Case [Axis] Litigation Case [Axis] Employee Benefit Trust Trust for Benefit of Employees [Member] Trading Symbol Trading Symbol U.S. government and agency securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Buy USD Sell Euro Buy USD Sell Euro [Member] Buy USD Sell Euro [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Benefit (expense) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Net income (loss) Net income (loss) Net income Net Income (Loss) Cash acquired Cash Acquired from Acquisition Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Short-term commercial paper borrowings Commercial Paper Liabilities and Equity Liabilities and Equity [Abstract] Prepaid taxes Prepaid Taxes Proceeds from sales of and distributions from noncurrent investments Proceeds from Sale and Maturity of Other Investments Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Unrealized gross losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract liabilities Contract with Customer, Liability Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Unfunded commitments to invest in venture capital funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Cost of sales Cost of Goods and Services Sold Service cost Defined Benefit Plan, Service Cost Unfunded commitments to invest in venture capital funds, anticipated payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Executive Category: Executive Category [Axis] Net losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Foreign Exchange Contract Foreign Exchange Contract [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Carrying Amount Reported Value Measurement [Member] Purchases of short-term investments Payments to Acquire Short-Term Investments Goodwill Goodwill Other neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Revenue recognized Disposal Group, Including Discontinued Operation, Revenue Hedging Relationship [Domain] Hedging Relationship [Domain] Measurement Basis [Axis] Measurement Basis [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Trulicity® Trulicity [Member] Trulicity [Member] Entity Small Business Entity Small Business Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Derivative, notional amount Derivative, Notional Amount Cash dividend declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Schedule of the contractual maturities of our investments in debt securities measured at fair value Investments Classified by Contractual Maturity Date [Table Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Basaglar® Basaglar Basaglar [Member] Basaglar [Member] Debt instrument, term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Asset impairment, restructuring, and other special charges (Note 5) Restructuring, Settlement and Impairment Provisions Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Accrued retirement benefits (Note 8) Liability, Defined Benefit Plan, Noncurrent Contingencies Commitments and Contingencies, Policy [Policy Text Block] Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Europe Europe [Member] Revenue (Note 2) Revenue Revenues Other, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest Schedule of fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Trading Arrangement: Trading Arrangement [Axis] Reclassification [Line Items] Reclassification [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Taltz® Taltz [Member] Taltz [Member] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Entity Shell Company Entity Shell Company Investments (Note 6) Noncurrent investments Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Verzenio® Verzenio [Member] Verzenio [Member] Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Derivative asset, notional amount Derivative Asset, Notional Amount Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Schedule of the fair value of available-for-sale securities in an unrealized gain or loss position Unrealized Gain (Loss) on Investments [Table Text Block] Cost of common stock in treasury Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Long-term debt Long-Term Debt Long-Term Debt Marketing, selling, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss (Note 10) Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Common Stock (no par value) Common Class A [Member] Asset Acquisition [Table] Asset Acquisition [Table] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Employee Litigation, July 2019 Ruling Employee Litigation, July 2019 Ruling [Member] Employee Litigation, July 2019 Ruling Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Variable rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Tabular List, Table Tabular List [Table Text Block] Other oncology Other Oncology [Member] Other Oncology [Member] Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Entity Address, Address Line One Entity Address, Address Line One Employee Litigation, July 2018 Ruling Employee Litigation, July 2018 Ruling [Member] Employee Litigation, July 2018 Ruling Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Acquisitions Asset Acquisition [Text Block] Other current liabilities Derivative Liability, Current Hedged Fixed Rate Debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Cost Portion at Other than Fair Value Measurement [Member] Business Acquisition [Axis] Business Acquisition [Axis] Income taxes payable Taxes Payable, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Costs, expenses, and other: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Acquisitions Business Combination Disclosure [Text Block] Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends Payable, Current Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Alimta® Alimta [Member] Alimta [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Tax Identification Number Entity Tax Identification Number Equity method investments Equity Method Investments Inventories Inventory, Net 5.0% Notes Due 2026 5.0% Notes Due 2026 [Member] 5.0% Notes Due 2026 Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Erbitux® Erbitux [Member] Erbitux [Member] Total Shareholder Return Amount Total Shareholder Return Amount Net product revenue Product [Member] Purchases of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) 0.500% Notes due 2033 .500% Notes Due 2033 [Member] .500% Notes Due 2033 [Member] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-Term Investments Other securities Other Debt Obligations [Member] Debt instrument, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current Assets Assets, Current [Abstract] Costs, expenses, and other Cost Of Sales, Operating Expenses, And Other-net Cost Of Sales, Operating Expenses, And Other-net Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Buy US Dollar Sell Chinese Yuan Buy US Dollar Sell Chinese Yuan [Member] Buy US Dollar Sell Chinese Yuan Immunology Immunology [Member] Immunology [Member] Description of Derivative Risk Management Derivatives, Policy [Policy Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Sell Chinese Yuan Sell Chinese Yuan [Member] Sell Chinese Yuan Royalty Agreement Terms Royalty Agreement Terms [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Cash dividends declared Dividends Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Other Stockholders' Equity, Other Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Retirement Benefits Retirement Benefits [Text Block] Other operating activities, net Other Operating Activities, Cash Flow Statement AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Versanis Bio, Inc. Versanis Bio, Inc [Member] Versanis Bio, Inc Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Net Cash Used for Investing Activities Increase in net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity securities Equity Securities, FV-NI, Current Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Forward-starting interest rate swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Other noncurrent liabilities Derivative Liability, Noncurrent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rates, percentage Effective Income Tax Rate Reconciliation, Percent Credit Facility [Axis] Credit Facility [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Additional cash proceeds Disposal Group, Including Discontinued Operation, Consideration Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair value of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Brazil BRAZIL Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Gains on sale of product rights Gain (Loss) on Disposition of Intangible Assets All Executive Categories All Executive Categories [Member] Milestone payment received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Other Other Product, Total [Member] Other Product, Total [Member] Other Liabilities Liabilities, Noncurrent [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Earnings (loss) per share: Earnings Per Share [Abstract] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Common stock Common Stock, Value, Issued 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five China CHINA Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative arrangement, rights and obligations percent (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Net periodic cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Schedule of fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Other noncurrent liabilities Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] 4.875% Notes Due 2053 4.875% Notes Due 2053 [Member] 4.875% Notes Due 2053 Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Other–net, (income) expense Other (income) expense Other Nonoperating Income (Expense) Litigation Case Type [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Diabetes Diabetes [Member] Diabetes [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Statement [Table] Statement [Table] Japan JAPAN Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] PEO Name PEO Name Other Other Product [Member] Other Product [Member] Baqsimi Baqsimi [Member] Baqsimi Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Asset-backed securities Asset-Backed Securities [Member] Net Cash Provided by Operating Activities Increase in net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other current liabilities Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Short-term investments Debt Securities, Available-for-Sale, Current Purchases of noncurrent investments Payments to Acquire Other Investments Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Depreciation and amortization Depreciation, Depletion and Amortization Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contingent value right, additional price per share (up to) (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Business Combination and Asset Acquisition [Abstract] Total Eli Lilly and Company shareholders' equity Equity, Attributable to Parent Biopharma Global Inc Biopharma Global Inc [Member] Biopharma Global Inc Commercial Paper Commercial Paper [Member] Proceeds from sales Proceeds From Sale Of Equity And Available For Sale Securities Proceeds From Sale Of Equity And Available For Sale Securities Net Unrealized Gains (Losses) on Available-For-Sale Securities Net unrealized gains/losses on available-for-sale securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Acquired IPR&D Expense Payments for Asset Acquisitions Payments for Asset Acquisitions Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net Investment Hedges Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Milestone Payments, Capitalized as Intangible Assets Milestone Payments, Capitalized As Intangible Assets [Member] Milestone Payments, Capitalized As Intangible Assets Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Disposal Group Classification [Domain] Disposal Group Classification [Domain] Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Credit Facility 2024 Credit Facility 2024 [Member] Credit Facility 2024 Long-term income taxes payable Accrued Income Taxes, Noncurrent Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Other noncurrent assets Derivative Asset, Noncurrent Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Schedule of significant milestones and revenue recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] 1.700% Notes due 2049 1.700% Notes Due 2049 [Member] 1.700% Notes due 2049 [Member] Property and equipment, net of accumulated depreciation of $10,767.8 (2023) and $10,233.4 (2022) Property, Plant and Equipment, Net Shares used in calculation of earnings (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Exercise Price Award Exercise Price Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] DICE Therapeutics, Inc. DICE Therapeutics, Inc [Member] DICE Therapeutics, Inc Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Percentage of nonperforming assets Debt Securities, Available-for-Sale, Unrealized Loss Position, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Debt securities, available-for-sale, unrealized loss position, qualitative disclosure, other, percentage of nonperforming assets. Net income (loss) Total reclassifications, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other immunology Other Immunology [Member] Other Immunology [Member] Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] Schedule of fair value information, assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Emergence Therapeutics AG Emergence Therapeutics [Member] Emergence Therapeutics Basic (in dollars per share) Earnings Per Share, Basic Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] COVID-19 antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc [Member] BioMarin Pharmaceutical Inc Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Buy GBP Sell USD Buy GBP Sell USD [Member] Buy GBP Sell USD Total other liabilities Liabilities, Noncurrent Proceeds from issuance of debt Proceeds from Issuance of Debt Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Investments in Equity and Debt Securities Fair Value of Financial Instruments, Policy [Policy Text Block] Stock repurchase program, remaining authorized amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Total Debt Securities, Available-for-Sale Document Information [Table] Document Information [Table] 0.625% Notes due 2031 .625% Notes Due 2031 [Member] .625% Notes due 2031 [Member] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Unrealized gross gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Net investment losses on equity securities Net investment losses on equity securities (Note 6) Equity Securities, FV-NI, Gain (Loss) Akouos Acquisition Akouos Acquisition [Member] Akouos Acquisition [Member] Sell Euro Sell Euro [Member] Sell Euro [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Losses expected to be reclassified in the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Net investment losses Gain (Loss) on Investments Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Reclassification [Table] Reclassification [Table] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Document Information [Line Items] Document Information [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Realized gross losses on sales Available For sale Securities And Equity Securities, FV-NI, Realized Loss Available For sale Securities And Equity Securities, FV-NI, Realized Loss Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Short-term borrowings and current maturities of long-term debt Debt, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Insider Trading Arrangements [Line Items] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Emgality® Emgality [Member] Emgality [Member] Acquired In-Process Research and Development (IPR&D) In Process Research and Development, Policy [Policy Text Block] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Noncontrolling interests Equity, Attributable to Noncontrolling Interest Maturity Date 2024 Maturity Date 2024 [Member] Maturity Date 2024 Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group Name [Axis] Disposal Group Name [Axis] Repayments of long-term debt Repayments of Long-Term Debt 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Sales rebates and discounts Sales Rebates And Discounts Sales Rebates And Discounts Common Stock in Treasury Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Income taxes (Note 7) Tax benefit Income Tax Expense (Benefit) Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Outside U.S. Non-US [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Cialis® Cialis [Member] Cialis [Member] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Employee compensation Employee-related Liabilities, Current Financial Instruments Fair Value Disclosures [Text Block] Net unrealized gains/losses on cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Foreign currency-denominated notes, designated as hedge Derivatives used in Net Investment Hedge, Net of Tax Name Trading Arrangement, Individual Name Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Other comprehensive income (loss), net of tax (Note 10) Other comprehensive (loss) income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Equity [Abstract] Equity [Abstract] Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Fair Value Hedging Fair Value Hedging [Member] Recognized actuarial (gain) loss Defined Benefit Plan, Amortization of Gain (Loss) Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents (Note 6) Cash and Cash Equivalents, at Carrying Value Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Senior Notes Due 2026, 2033, 2053 And 2063 Senior Notes Due 2026, 2033, 2053 And 2063 [Member] Senior Notes Due 2026, 2033, 2053 And 2063 Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Realized gross gains on sales Available For Sale Securities And Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combinations Business Combinations Policy [Policy Text Block] 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Long-Term Debt, Excluding Current Maturities Schedule of activity related to our available-for-sale securities Gain (Loss) on Securities [Table Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Interest Rate Contracts Interest Rate Contract [Member] Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Humulin® Humulin [Member] Humulin [Member] Schedule of amounts recorded for contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Humalog® Humalog [Member] Humalog [Member] Jardiance Jardiance [Member] Jardiance [Member] Revenue Revenue from Contract with Customer [Text Block] Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents at January 1 Cash and Cash Equivalents at September 30 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Cover [Abstract] Cover [Abstract] Forteo® Forteo [Member] Forteo [Member] U.S. UNITED STATES Defined Benefit Pension and Retiree Health Benefit Plans Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Trajenta Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Dividends paid Payments of Dividends Other noncurrent liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Roche Roche [Member] Roche [Member] Short-term investments (Note 6) Short-Term Investments Defined Benefit Pension Plans Pension Plan [Member] Cash Flow Hedging Cash Flow Hedging [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Offsetting Assets [Line Items] Offsetting Assets [Line Items] Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] 4.7% Notes Due 2033 4.7% Notes Due 2033 [Member] 4.7% Notes Due 2033 Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Mounjaro® Mounjaro [Member] Mounjaro [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Schedule of derivative instruments Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Mortgage-backed securities Collateralized Mortgage-Backed Securities [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Fair value of securities in an unrealized gain position Debt Securities, Available-For-Sale, Unrealized Gain Position Debt Securities, Available-For-Sale, Unrealized Gain Position Zyprexa Zyprexa [Member] Zyprexa [Member] Eli Lilly and Company Shareholders' Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Noncontrolling Interests Noncontrolling Interest [Member]